TXG10x Genomics, Inc.

Nasdaq 10xgenomics.com


$ 22.35 $ -0.18 (-0.8 %)    

Friday, 13-Sep-2024 15:59:59 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 22.37
$ 22.35 x 100
$ 22.38 x 100
-- - --
$ 15.28 - $ 57.90
995,838
na
2.7B
$ 1.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 04-30-2024 03-31-2024 10-Q
3 02-15-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-16-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 02-18-2022 12-31-2021 10-K
12 11-05-2021 09-30-2021 10-Q
13 08-06-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 02-26-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-12-2020 06-30-2020 10-Q
18 05-12-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 10x-genomics-announces-its-chromium-single-cell-gene-expression-and-xenium-in-situ-platforms-were-used-in-a-publication-featured-on-the-cover-of-cancer-cell-shedding-light-on-the-role-of-fibrotic-scars-in-glioblastoma-treatment-recurrence

In the September 9 cover article of Cancer Cell, researchers integrated 10x single cell and spatial technologies to identify a ...

 stephens--co-reiterates-overweight-on-10x-genomics-maintains-30-price-target

Stephens & Co. analyst Mason Carrico reiterates 10x Genomics (NASDAQ:TXG) with a Overweight and maintains $30 price target.

 leerink-partners-initiates-coverage-on-10x-genomics-with-outperform-rating-announces-price-target-of-35

Leerink Partners analyst Mike Kratky initiates coverage on 10x Genomics (NASDAQ:TXG) with a Outperform rating and announces ...

 gold-rally-loses-steam-as-treasury-yields-stabilize-dollar-rebounds-6-miner-stocks-see-declines-on-wednesday

Gold rally loses momentum as dollar rebounds and Treasury yields stabilize. Gold mining stocks also decline due to dip in gold ...

 ubs-maintains-neutral-on-10x-genomics-lowers-price-target-to-25

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $30 to $25.

 morgan-stanley-maintains-overweight-on-10x-genomics-lowers-price-target-to-46

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $...

 10x-genomics-13g-filing-shows-ark-investment-management-llc-reported-a-1075-stake-as-of-july-31-2024

- SEC Filing

 10x-genomics-cfo-justin-mcanear-will-resign-effective-aug-30-adam-taich-appointed-cfo-since-aug-12

10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive ...

 10x-genomics-lowers-fy24-sales-guidance-from-640m-660m-vs-66306m-estimate

2024 Financial Guidance 10x Genomics is updating its outlook for the full year 2024. The company now expects revenue to be in ...

 10x-genomics-q2-2024-gaap-eps-032-beats-048-estimate-sales-153104m-beat-150089m-estimate

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.48) b...

 canaccord-genuity-maintains-buy-on-10x-genomics-lowers-price-target-to-32

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and lowers the price target from $50 to...

 jefferies-upgrades-10x-genomics-to-buy-maintains-price-target-to-24

Jefferies analyst Tycho Peterson upgrades 10x Genomics (NASDAQ:TXG) from Hold to Buy and maintains the price target from $24...

 b-of-a-securities-maintains-neutral-on-10x-genomics-lowers-price-target-to-25

B of A Securities analyst Derik De Bruin maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from...

 jp-morgan-downgrades-10x-genomics-to-neutral-lowers-price-target-to-20

JP Morgan analyst Rachel Vatnsdal downgrades 10x Genomics (NASDAQ:TXG) from Overweight to Neutral and lowers the price targe...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION